efficacy of meglumine antimoniate-loaded nanoparticles for cutaneous leishmaniasis: a systematic review.

Nanotechnology is a promising strategy to improve existing antileishmanial agents. To explore the evidence of encapsulated meglumine antimoniate for cutaneous leishmaniasis treatment in animal models. The studies were recovered from PubMed, Scopus, EMBASE, LILACS, WoS and Google according to eligibility criteria following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) and the Population, Intervention, Comparison, Outcomes and Study design (PICOS) strategy. Study appraisal was assessed using the Animal Research Reporting of Experiments, SYstematic Review Centre for Laboratory animal Experimentation (SYRCLE) and Grading of Recommendations Assessment, Development and Evaluation (GRADE) recommendations. Five studies were included. Liposomes, metallic and polymeric nanoparticles were tested in BALB/c mice against , or . Few studies were found to meet the eligibility criteria. All formulations had a significant efficacy, similar to the meglumine antimoniate reference treatment concerning the lesion size and parasite burden. The studies had a high and moderate risk of bias, and the confidence in cumulative evidence was considered low. Therefore, we encourage the development of high-quality preclinical studies. PROSPERO register CRD42020170191.